Watch below: Dr. Hutson (Thomas Hutson, DO, PharmD, PhD FACP), lead investigator of Study 205, discusses LENVIMA + everolimus in adults living with advanced renal cell carcinoma (aRCC) who received one prior anti-angiogenic therapy. Find the full Prescribing Information here: bit.ly/LenvimaPI

TTUHSC and the UMC Cancer Center rapidly becoming a regional destination academic cancer center. Come join our team. linkedin.com/posts/thomas-h…

🚨#IKCS24 Proceedings is out! kidney-cancer-journal.com/IKCSNA-Proc.php 📕flipbook: kidney-cancer-journal.com/IKCS24-Proc2.p… 👉25 years of #ICKS24 - Special editorials by Brian Rini, MD Thomas Hutson, DO, PharmD, PhD FACP Salvatore La Rosa Kidney Cancer

Surprised and honored by my latest research rankings. #9 Lifetime RCC Top 0.26% Medicine 0.31% Oncology….To God be the Glory. #cureCancer #CureRCC #westTexasProud #TTUHSC #UMC

Kidney Cancer Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ Thomas Hutson, DO, PharmD, PhD FACP Salvatore La Rosa Brian Rini, MD Michael Staehler Senthil Samy, PhD Congratulations to all involved with #IKCSNA24. (rt IKCC Kidney Cancer)

Now on the LENVIMA® (lenvatinib) YouTube channel: Dr. Hutson (Thomas Hutson, DO, PharmD, PhD FACP) describes treatment considerations for advanced renal cell carcinoma (aRCC). Find the full Prescribing Information here: bit.ly/LenvimaPI #LENVIMA #aRCC

@ASCO25 Special release: 🚨ROUNDTABLE: Cabozantinib in RCC: Clinical Insights and Future Directions 📺Video: tinyurl.com/KCJCabo1 📕TRANSCRIPT: kidney-cancer-journal.com/KCJ23n2-roundt… Thomas Hutson, DO, PharmD, PhD FACP Texas Tech University Health Sciences Center Michael Serzan, MD Dana-Farber DrMarcMatrana Ochsner Health #RCC #Cabozantinib

Powerful talk by Rana McKay, MD, FASCO with an overview on #HIF2 inhibitors treatment landscape, #LITESPARK clinical trials comprehensive results and updates. Exciting data and future opportunities for #RCC therapy armentarium. #ASCO25 ASCO The ASCO Post Journal of Clinical Oncology Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO

25 years of coming to this meeting. First time as a cancer center director. #ASCO25 #TTUHSC #UMC #curecancer #curekidneycancer

A consistent DFS difference over time (now a long time) clearly shows activity and likely increased cure and not just delay (as with S-TRAC). Still effect size is modest. Need better molecular diagnostic tests for patient selection and likely combos in (neo)adj. ❤️ this progress

Thank you for your support MJ!! We even had a patient cross institutions and move from Duke to Penn State during the trial! #asco25

TTUHSC School of Medicine UMC Health System to host West Texas Cancer Symposium in June 7, 2025 kcbd.com/2025/05/21/ttu… Texas Tech University Health Sciences Center TTUHSC Department of Surgery Thomas Hutson, DO, PharmD, PhD FACP Tyler Mouw

Proud to be part of this pivotal trial and to have learned so much from Dr. Srinivasan and our patients. ⁦National Cancer Institute⁩⁩ ⁦The James⁩ ⁦Ohio State Wexner Medical Center Urology Dept.⁩ ⁦Kimryn Rathmell⁩ ⁦Kidney Cancer⁩ ⁦KidneyCAN⁩ ⁦IKCC Kidney Cancer⁩ ⁦⁦Kidney Cancer Canada⁩

Great news.

It is sad day for the GU Oncology field losing someone like Brian. He was a class act surgeon, researcher and human being. I miss our times and work together Cleveland Clinic MUSIC Urology Eric Klein JAGarciaMD Brian Rini, MD @TimGilliganMD Cleveland Clinic Urology Dr. Jihad Kaouk

This is huge. Congrats to Tom Powles Barts Experimental Cancer Medicine Centre & team who took this from a brilliant paper in nature in 2021 to a paradigm-shifting + P3 trial. Bladder Cancer Advocacy Network IBCG

Indeed, Tom Powles continues to tailor, guide and define the Standard of Care in Bladder Cancers one year after another.

ADCs all the way with B7H3, courtesy of Paul D. Rennert

Proud of Cristiane D Bergerot (mentored by Tom Powles) who worked closely with leaders in the field (Toni Choueiri, MD Laurence Albiges Viraj Master Elizabeth Plimack MD Viktor Grünwald Brian Rini, MD Sarah P. Psutka MD MS Thomas Hutson, DO, PharmD, PhD FACP) & patient advocates (via @kidneycancer) to develop a new iteration of the #FKSI. This

Amazing work Cristiane D Bergerot & everyone else for practical & important contributions! Sumanta K. Pal, MD, FASCO Tom Powles Uromigos Toni Choueiri, MD Laurence Albiges Elizabeth Plimack MD Viraj Master Viktor Grünwald Brian Rini, MD Sarah P. Psutka MD MS Thomas Hutson, DO, PharmD, PhD FACP